47 results about "Tumor control" patented technology

Embodiments herein provide a non-invasive tracking system that accurately predicts the location of tumors, such as lung tumors, in real time, while allowing patients to breathe naturally. This is accomplished by using Electrical Impedance Tomography (EIT), in conjunction with spirometry, strain gauge and infrared sensors, and by using sophisticated patient-specific mathematical models that incorporate the dynamics of tumor motion. With the direction and speed of lung tumor movement successfully tracked, radiation may be effectively delivered to the lung tumor and not to the surrounding healthy tissue, thus increased radiation dosage may be directed to improving local tumor control without compromising functional parenchyma.

The present invention provides compositions and methods for increasing therapeutic gain in radiotherapy and chemotherapy for proliferating malignant or nonmalignant disease to produce high probability of tumor control with low frequency of sequelae of therapy by administering a therapeutically effective amount of a histone deacetylase inhibitor. The compounds are capable of simultaneously stimulating the epithelium regrowth, inhibiting the fibroblast proliferation, decreasing the collagen deposit, suppressing the fibrogenic growth factor, subsiding the proinflammatory cytokine and modulating the expression of cell cycle genes, tumor suppressors and oncogenes, and are useful to increase the therapeutic gain in radiotherapy and chemotherapy, which results in decrease of skin swelling and inflammation, promotion of epithelium healing in mucosa and dermis, decrease of xerostomia, prevention / reduction of severity of plantar-palmar syndrome, prevention of tissue fibrosis, ulceration, necrosis and tumorigenesis, and increase of tumor growth inhibition and tumor therapy effectiveness.

An improved method and products for the primary hormonal treatment of early stage, low and intermediate risk prostate cancers by prostatic implants of androgen suppressive drugs formulated as fused with a lipoid carrier or encapsulated in microcapsules or in Silastic capsules is provided. Such prostatic implants renders a constant slow-release of their contents to the prostate for extended periods by biodegradation and diffusion. It facilitates higher prostatic and lower systemic concentrations of androgen suppressive hormones. Because of their high prostatic and lower systemic concentrations, tumor control is much improved and the their systemic toxicity is minimized. Tumor control after such primary hormonal implant treatment is followed by clinical examinations and the biochemical tumor control is followed by periodic estimations of serum levels of PSA and acid phosphatase. More complex and expensive surgery or radiation therapy for this group of good prognostic early stage prostate cancer is reserved for those patients failing to this primary hormonal treatment. It will preserve potency more than by surgery or radiation therapy. Furthermore, it would reduce the cost of treatment for early stage prostate cancer significantly. Androgen suppressive hormonal implants to the prostate before, during or after lower dose conventional radiation therapy would also facilitate equal or better cure rates of localized prostate cancer as compared to the more complex and toxic higher dose radiation therapy.

A mathematical contouring algorithm that automatically determines the planning volume of a sarcoma prior to designing a brachytherapy treatment plan. The algorithm, utilizing computational geometry, numerical interpolation and artificial intelligence (AI) techniques, returns the planning volume in digitized and graphical forms in a matter of minutes. Such an automatic procedure reduces labor time and provides a consistent and objective method for determining planning volumes. In addition, a definitive representation of the planning volume allows for sophisticated brachytherapy treatment planning approaches to be applied when designing treatment plans, so as to maximize local tumor control and minimize normal tissue complications.

The present invention provides a new approach for cancer treatment by utilizing gene therapy combined with radiation therapy to enhance cytotoxicity in malignant cells. Specifically, the present invention demonstrates that molecular chemotherapy with the cytosine deaminase gene and 5-fluorocytosine is an effective radiosensitizing strategy which may lead to substantial improvement in tumor control, with less normal tissue toxicity than conventional systemic administration of 5-fluorouracil, that would translate into improved cure rates and better survival. A noninvasive method is described for continuous in vivo monitoring of 5-fluorouracil production via magnetic resonance spectroscopy. An adenovirus encoding cytosine deaminase gene which selectively replicates in tumor cells with a defective p53 pathway was constructed. Also provided is an adenovirus which encodes a fusion protein of cytosine deaminase and uracil phosphoribosyltransferase.

Relating to the technical field of pharmaceutical preparations, the invention provides an antibody composition preparation composed of Trastuzumab and Pertuzumab. The antibody composition preparation has better tumor treatment activity. Compared with the independent treatment of Trastuzumab and Pertuzumab, the composition preparation shows a synergistic effect of the two antibodies, and can reach a tumor control rate of 92.43%. And the preparation provided in the invention has better stability, thus being in favor of long-term preservation of the antibody composition preparation. The antibody composition preparation provided in the invention is applicable to preparation of drugs treating diseases or symptoms suited to anti-HER2 antibody therapy. During application, the antibody composition preparation disclosed in the invention is used with a chemotherapeutic agent jointly or sequentially.

Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic T cell response. Portions of mesothelin which induce such responses are identified. Vaccines can be either polynucleotide- or polypeptide-based. Carriers for raising a cytolytic T cell response include bacteria and viruses. A mouse model for testing vaccines and other anti-tumor therapeutics and prophylactics comprises a strongly mesothelin-expressing, transformed peritoneal cell line.

The present invention offers an alternative for cancer treatment where radiation, thermotherapy, or another therapeutic modality must be delivered to an internal cavity of a subject, for example to treat mouth, anal, cervical, and vaginal cancers. The invention is a new approach that builds on recent results in 3D printing and steerable needle motion planning to create customized implants containing customized curvature-constrained internal channels that fit securely, minimize air gaps, and precisely guide treatment sources through internal printed channels to accurately reach tumors and minimize damage to healthy tissue.

The invention discloses an anti-tumor controlled release nanocomposite and a preparation method thereof. The nanocomposite utilizes nano diamonds after carboxylation treatment as carriers, and comprises adsorption enzyme self degradation chains and cell-penetrating peptides. The preparation method is implemented as follows: dispersing nano diamonds after carboxylation treatment of a strong acid in a dimethyl sulfoxide aqueous solution, adding an anti-tumor drug connected with a self degradation chain, and stirring under room temperature to obtain a composite; and dispersing the obtained composite in water, adding the cell-penetrating peptides, and stirring and drying at room temperature to obtain the anti-tumor controlled release nanocomposite. The nano carrier composite in the invention is simple and convenient in preparation, has no toxicity and pollution, and is easy for industrialization. In vitro research shows that the composite can realize controlled release of an anti-tumor drug, enhance the killing effect of the drug on tumors, and provide a new material and method for drug transport.

The invention discloses an extraction method of a land slug and an anti-lung cancer application of the land slug. The extraction method comprises the following steps: (1) carrying out vacuum freeze-drying on the land slug, adding purified water and then carrying out water bath agitation, adding a high-concentration ethanol solution, evenly agitating until the ethanol concentration is 60-70%, standing and then carrying out solid-liquid separation; (2) clarifying and intercepting the liquid obtained in the step (1) by adopting an inorganic ceramic membrane system, so as to obtain total clear liquid of the land slug; (3) concentrating the total clear liquid of the land slug obtained in the step (2) by a reverse osmosis membrane; and (4) concentrating and drying ultra-filtrate obtained in the step (3), so as to obtain water-soluble land slug powder. The molecular weight of the land slug powder obtained by the method is concentrated between 20,000 and 30,000, and has a significant antitumor effect; the tumor control rate is higher than that of cinobufagin and close to that of cyclophosphamide. The water-soluble land slug powder disclosed by the invention is used for treating a lung cancer, and is efficient and low-toxicity.

The invention relates to an immunogene therapeutic drug for chronic hepatitis B and a preparation method for the immunogene therapeutic drug. The active component of the drug is a replication-competent recombinant vector pSVK-dSFValpha-IRES-hIL-12 (for short, pSVK-HBVE), which is constructed by taking a pSVK carrier as a starting carrier and carries a fusion gene dSFValpha-IRES-hIL12. An antibody targeting interferon alpha and human IL-12 are co-expressed in the replication-competent recombinant vector pSVK to construct a humanized HBsAg dsFv antibody, human interferon-alpha and interleukin-12 fusion expression vector pSVK-dSFValpha-IRES-hIL-12, the fusion expression vector is efficiently expressed in an eukaryotic cell and in vitro, the combined application of human IL-12 and human IFN-alpha has an important synergistic effect during the tumor control process, and a safe and efficient immunogene therapeutic drug is provided for gene therapy of chronic hepatitis B.

The invention discloses a wedelia trilobata anti-tumor extract and preparation and application methods thereof. The wedelia trilobata anti-tumor extract is prepared by adding solvent into wedelia trilobata powder for extraction, filtering and decompression-concentrating extracted liquor to obtain a total extract, mixing the total extract with water into a suspension, performing extraction sequentially through petroleum ether and ethyl acetate and performing decompressed recovery to obtain a petroleum ether solution, an ethyl acetate solution and a aqueous solution, wherein the petroleum ether solution contains one eudesmene type sesquiterpene lactone, five enantiotopic kaurane type diterpenoid compounds, two oleanane type triterpenes, one cycloartane type triterpene, one sterol compound, two dipeptide compounds and one caffeate compound. The prepared wedelia trilobata anti-tumor extract is high in yield, simple in technical process, low in cost and applicable to large-scale preparation, and meanwhile, has broad-spectrum anti-tumor activity and can serve as an active component applied to tumor control and treatment drugs.

The invention relates to an anticancer sustained release gel injection with stine drugs, comprising sustained release microspheres with stine drugs, a amphiphilic block copolymer, solvent and releasing moderator; wherein, the mixture of the amphiphilic block copolymer and the solvent possesses sensitive gelation property; after in vivo injection, the injection can be transformed into nonflowing, biodegradable gel insoluble in water; the insoluble gel can release the contained drugs in local tumor for weeks, even months. Intra-tumor injection or local injection can be used to treat different tumors and unresectable tumors, control late complications and the postoperative residual tumor cell recurrent, reinforce the effect of radiotherapy and chemotherapy and the effect of radiotherapy particles; nimustine and carmustine and other stines; the amphiphilic block copolymer is a PLGA-PEG-PLGA copolymer with the molecular weight of PEG 1200-1600 accounting for 20% of the amphiphilic block copolymer weight; in the poly lactide coglycolide copolymer, the molar ratio of glycolide and lactide is 6:1.

An improved method and products for the hormonal treatment of breast cancer by breast implants of anti-estrogens and steroid hormones in formulations as fused with a lipoid carrier or encapsulated in microcapsules or in Silastic capsules is provided. Such breast implants renders a constant slow-release of their contents to the breast tissue for extended periods by biodegradation and diffusion. It facilitates higher breast tissue concentrations of anti-estrogen and hormonal compositions. Because of their high concentration in the breast and lower systemic distribution, tumor control is much improved and the their systemic toxicity is minimized. An added beneficial effect of these breast implants on breast cancer is mediated by the inhibition of hypothalamic-pituitary LHRH, FSH and LH secretion by these composition's systemic contents. It is also an effective prophylaxis against breast cancer. Furthermore, it reduces the cost of hormonal treatment of breast cancer. Anti-estrogen hormonal implants to the breast as concomitant hormonal treatment with conventional radiation therapy also facilitates improved tumor control and cure rates of breast cancer.

The invention discloses a photosensitive medicinal preparation containing amino poly-carboxylic acid modification tetraphenylporphyrin compound. Each unit dose contains 1mg-100mg of the amino poly-carboxylic acid modification tetraphenylporphyrin compound. The each unit dosage is the total amount of the medicinal preparation used everyday. The amino poly-carboxylic acid modification tetraphenylporphyrin compound can be used in combination with other medicine or is singly used. Through addition of a drug carrier which is acceptable in pharmacy, the amino poly-carboxylic acid modification tetraphenylporphyrin compound accounts for 0.5%-40% the total weight of the medicinal preparation and can be prepared to any dosage form accepted clinically. The invention further provides application of the medicinal preparation on preparation of photosensitive antitumor drug and in the near infrared fluorescence imaging filed. The photosensitive medicinal preparation containing the amino poly-carboxylic acid modification tetraphenylporphyrin compound is low in toxicity, convenient to apply, wide in tumor suppression spectrum, good in tumor control rate, good in effect of malignant tumor treatment through photodynamic therapy, high in fluorescence quantum yield and optical stability in a near-infrared area, good in biocompatibility, capable of having a certain ability of penetrating the biological barrier, and wide in application prospect in the near infrared fluorescence imaging field.

The present invention provides a new approach for cancer treatment by utilizing gene therapy combined with radiation therapy to enhance cytotoxicity in malignant cells. Specifically, the present invention demonstrates that molecular chemotherapy with the cytosine deaminase gene and 5-fluorocytosine is an effective radiosensitizing strategy which may lead to substantial improvement in tumor control, with less normal tissue toxicity than conventional systemic administration of 5-fluorouracil, that would translate into improved cure rates and better survival. Also provided is a noninvasive method for continuous in vivo monitoring of 5-fluorouracil production via magnetic resonance spectroscopy.

The invention discloses a stereotactic radiotherapy device and an implementation method of the stereotactic radiotherapy device. Due to the face that electrical control is achieved through eight motors, the defects that an existing gamma ray stereotactic radiotherapy device is complex in structure and high in adjustment difficulty are overcome. Meanwhile, the stereotactic radiotherapy device has the advantages that the device is simple, cost is low, practicability and accuracy are high, adjustment and maintenance are easy, and the transmission dosage in the treatment process is small. The stereotactic radiotherapy device makes a great contribution to the field of treatment of the radiosurgery, and is sure to make a great contribution to tumor control, side effect reduction and the improvement of life quality of patients.

The invention discloses a traditional Chinese medicine composition for resisting a liver cancer and a lung cancer. The traditional Chinese medicine composition is prepared from a rhizoma paridis total saponin extract, a curcuma extract and a dioscorease rhizome extract of which the mass ratio is 1:(10-20):(1-10). An in-vitro MTT process activity test proves that the traditional Chinese medicine composition disclosed by the invention has a growth inhibition effect on an LA795 lung cancer cell line and an HepG2 hepatoma cell line; IC50 respectively can be up to below 20mg / mL (dose). An in-vivo experiment proves that the traditional Chinese medicine composition disclosed by the invention has a significant growth inhibition effect on mice T739 lung cancer metastasis in mice, an HepA liver cancer and an H22 lung cancer, and the tumor control rates respectively can be up to 53%, 55% and 57%. Compared with component administration of components forming the composition, the tumor control effect of the composition disclosed by the invention has a synergistic enhancement effect.

A therapy system includes a diagnostic image scanner (12) that acquires a diagnostic image of a target region to be treated. A planning processor (70) is configured to generate a patient specific adaptive radiation therapy plan based on patient specific biomarkers before and during therapy. A first set of patient specific biomarkers is determined then used for the determination of a first normal tissue complication probability (NTCP) model and a first tumor control probability (TCP) model. A radiation therapy device (40) administers a first dose of radiation to the target region with a protocol based on the first NTCP model and the first TCP model. A second set of patient specific biomarkers is determined. A relationship between the first set and second set of patient specific biomarkers is used to determine a second NTCP model and a second TCP model. The radiation therapy device (40) administers a second dose of radiation to the target region with a protocol based on the second NTCP model and second TCP model.

Relating to the technical field of pharmaceutical preparations, the invention provides an antibody composition preparation composed of Trastuzumab and Pertuzumab. The antibody composition preparation has better tumor treatment activity. Compared with the independent treatment of Trastuzumab and Pertuzumab, the composition preparation shows a synergistic effect of the two antibodies, and can reach a tumor control rate of 92.43%. And the preparation provided in the invention has better stability, thus being in favor of long-term preservation of the antibody composition preparation. The antibody composition preparation provided in the invention is applicable to preparation of drugs treating diseases or symptoms suited to anti-HER2 antibody therapy. During application, the antibody composition preparation disclosed in the invention is used with a chemotherapeutic agent jointly or sequentially.

The invention provides a method and device for acquiring a radiation therapy plan. The method comprises the steps of acquiring a leaf flux pattern according to dose constraints; segmenting the leaf flux pattern into subfields; and acquiring a radiation therapy plan by using the subfields. According to the technical scheme of the invention, the radiation therapy plan can be acquired based on the leaf flux pattern rather than a pencil beam flux pattern, so that even if an MLC (Multi Leaf Collimator) comprises different widths of leaves, the MLC can be effectively used to shield rays irradiated on normal organs when the radiation therapy plan is used. The acquisition method of the radiation therapy plane can reduce the burden of doctors. The radiation therapy plan is more rational and reliable, the treatment quality is greatly improved, the dose for a tumor can be substantially increased, the dose for normal organs is reduced, the tumor control rate is improved, and the occurrence rate ofcomplications of the normal organs is reduced. In addition, the leaf flux pattern can be ensured to completely correspond to the MLC field in size, the controllability of the algorithm is improved, and the error is reduced.

A sustained-release gel injection comprises angiogenesis inhibitor, amphiphilic block copolymer, solvent and release regulator, wherein the mixture of amphiphilic block copolymer and solvent has temperature sensitive gelatinization characteristic, and can automatically become non-flowing degradable water insoluble gel, which can locally and slowly release drug at tumor foci for several weeks to several months, after injection into body. The preparation can be injected into or around tumor for treating solid tumors at different stages and metastatic tumors with remarkably reduced systemic toxicity of drug. The angiogenesis inhibitor is selected from alemtuzumab,ibritumomab, bevacizumab, rituximab, gemtuzumab ozogamicin, panitumumab, trastuzumab, celebrex, refecoxib, tositumomab, endostatain, engiostatin, toxitumomab, and cetuximab. The preparation has effects of controlling residual tumor cell relapse after operation and tumor can not be excised via operation, controlling complications at late stage of tumor, and enhancing treatment effect of chemotherapy and radiotherapy (particularly radioactive particles).

The invention relates to the technical field of medicines and in particular relates to application of an ethyl acetate part of caper in preparation of antitumor drugs. The invention further provides apreparation method of the ethyl acetate part of caper. The preparation method comprises the following steps: (1) with caper powder, performing reflux extraction with an alcohol aqueous solution, filtering, and performing vacuum concentration to obtain extract; and (2) dispersing the extract with water, sequentially extracting with petroleum ether, chloroform and ethyl acetate, concentrating and drying, thereby obtaining the ethyl acetate part. Possible positions achieving an antitumor effect in the ethyl acetate part prepared in the invention are total alkaloids; the tumor control rate of theethyl acetate part on transplanted H22 tumor-bearing mice reaches 38.2%; the life of ascitic tumor mice can be obviously prolonged; HE staining results show that tumor tissue cells are sparsely arranged, large-area necrosis occurs and great cytoplasm vacuolization is caused; and meanwhile, the ethyl acetate part does not have any obvious influence on immune organs, hepatic and renal functions andblood routine examination and has potential of being developed into a novel antitumor drug.

Disclosed is a method and system for determining cancer therapy effects via imaging omics features, including a synthesis unit which is used for matching the patient positioning image with the timingimages in the treating process, wherein the data on the positioning image is mapped to the timing images in the treating process; the selected part on the timing image is cut into multiple corresponding area of interest; an acquisition unit used for extrating imaging omics features with stability on the patient image; and an analysis unit used for assessing the treating effects of the patients based on the changes of the imaging omics feature parameters in the areas of interest along with the treatment progress. The scheme has the following advantages of high stability and repeatability; the timing image optic features changes sharply along with the treatment gradation and accumulated dose; the early individuation prediction of cancer recurrence and metastasis or radiation damage to the normal tissue are obtained, so the control probability of the cancer is improved while the radiation damage to the normal tissue and cancer relapse are reduced.

The invention discloses an oval-body-adjustable gynecological close-range back-loading source applicator, and solves the problems that in the prior art, the source applicator cannot adapt to cervicalcancer patients in various vaginal environments, errors of radiotherapy dosage are easily caused, tumor control fails, and side effects are aggravated. The source applicator comprises a middle connecting frame consisting of a connecting frame main body, and is characterized in that in an elbow mounting hole at the upper end of the middle connecting frame, a source applicator bent is inserted; an oval body left hemisphere and an oval body right hemisphere are symmetrically arranged on the two sides of the middle connecting frame respectively and are each composed of a hemispheric shell, and inwards-concave cavities are formed in the opposite sides of the two hemispheric shells respectively. The oval body left hemisphere and the oval body right hemisphere are connected with the middle connecting frame through the oval body adjusting mechanism. The source applicator is reasonable in design, compact in structure, capable of meeting the treatment requirements of different types of middle and advanced cervical cancer radiotherapy patients, easy and convenient to operate, capable of effectively improving the radiotherapy quality, free of trauma, small in side reaction after treatment, economical, practical and good in patient medical compliance.

The invention provides a method and a device for detecting tumor neoantigen polypeptide. The method comprises the following steps of: acquiring somatic mutation and embryonic system mutation of tumortissues; carrying out HLA (Human Leukocyte Antigen) typing by utilizing sequencing data of a tumor control blood cell sample to obtain an HLA typing result; carrying out neoantigen polypeptide prediction on the somatic mutation and the embryonic system mutation by utilizing the HLA typing result to obtain candidate neoantigen polypeptides; and scoring and sequencing the candidate neoantigen polypeptides, wherein the neoantigen polypeptide with the highest score is the neoantigen polypeptide. New antigen polypeptide prediction is carried out by obtaining the sum of mutations comprising two sources, the sources of the mutations are more comprehensive, and the prediction result is relatively more accurate. The predicted candidate neoantigen polypeptides are scored and sorted, and the subsequent neoantigen polypeptide with the highest score is used as the neoantigen polypeptide, so that the more accurate neoantigen polypeptide can be conveniently obtained, and the guiding significance of subsequent immunotherapy medication is further improved.

The invention relates to itraconazole applied to treatment of gastric cancer, lung cancer and liver cancer, and a composition of the itraconazole. The daily dose of the itraconazole is 0.1-5000mg, and the itraconazole has good curative effect when the daily dose is 200mg. The itraconazole and the composition of the itraconazole disclosed by the invention have the beneficial effects that by subcutaneous injection of the itraconazole solution or the composition, the survival time of high and low-dose groups of SPF-grade Konmin mice that have liver cancer H22 can be prolonged. The itraconazole or the composition of the itraconazole has obvious inbibitional effect on Lewis lung cancer of mice in comparison with the control group according to the influence on subcutaneous tumor of the Lewis lung caner, the growth rate (P(0.01) of the tumor can be slowed down; the size (P(0.01) of the tumor is reduced; and the tumor control rate is respectively 43.0% and 45.6% after the treatment is ended. The itraconazole or the composition of the itraconazole influences positive staining of the human gastric cancer tissue VEGF (Vascular Endothelial Growth Factor) in cell cytoplasm, and the VEGF positive expression of a 0.9% sodium chloride solution group is obviously higher than that of the itraconazole group (P(0.05).

Disclosed is a method of utilizing deuterons (nuclear particles consisting of a proton and a neutron) for charged particle radiotherapy. Compared with proton therapy, at their maximum treatment depth of 66 mm, 125 MeV deuterons possess 82-85% less beam straggling than protons. This difference enables better protection of radiosensitive critical tissues that may be in contact with a tumor. Alternatively, it enables higher doses to be delivered to the tumor, resulting in better tumor control. The implementation of deuteron therapy interchangeably alongside proton therapy requires minor modifications at modest cost to many existing proton therapy systems and provides a clinically useful hybrid particle therapy facility. A free-standing deuteron therapy facility that employs only deuterons is also described.